Location History:
- Les Ponts-de-Cé, FR (2008)
- les-Ponts-de-Ce, FR (2007 - 2015)
Company Filing History:
6 out of 9 
1 out of 505 
1 out of 24 Years Active: 2007-2015
Title: Alain Burgos: A Remarkable Inventor in Medicinal Chemistry
Introduction:
Alain Burgos, a French inventor hailing from Les Ponts de Ce, has made significant contributions to the field of medicinal chemistry through his innovative approaches and valuable patents. With eight patents to his name, Burgos has established himself as a notable figure in the development of pharmaceutical compounds. This article delves into his latest patents, career highlights, collaborations, and the impact of his work on the industry.
Latest Patents:
Burgos' latest patents demonstrate his expertise in the synthesis of pharmaceutical compounds. One of his notable inventions is the method for preparing nebivolol, a beta-blocker used in the treatment of hypertension and heart failure. This improved process of synthesizing nebivolol's key intermediate has the potential to enhance its production efficiency and overall pharmaceutical quality.
Another significant patent is the method for chemo-selective enzymatic hydrolysis of a diester compound to obtain a monoester monoacid compound. This patent discloses a technique involving enzymatic hydrolysis, which selectively breaks down one of the two ester groups in a compound, leading to the formation of desired monoester monoacid compound. Such a method holds promise for the efficient synthesis of numerous pharmaceutical intermediates and compounds.
Career Highlights:
Alain Burgos has contributed his expertise to various well-known companies in the pharmaceutical industry, including Zach System and Teva Pharmaceutical Industries Limited. While specific details about his roles are undisclosed, Burgos' involvement with such reputable organizations indicates his significant contributions to research and development in medicinal chemistry.
Collaborations:
Throughout his career, Burgos has collaborated with esteemed professionals in the field of pharmaceutical research. Notably, he has worked alongside Sylvie Blanchet and Yvon Derrien, who are recognized for their expertise in medicinal chemistry. These collaborations demonstrate Burgos' commitment to teamwork and his willingness to explore new perspectives to drive innovation further.
Conclusion:
Alain Burgos has demonstrated his expertise in medicinal chemistry through his eight patents and contributions to renowned companies in the pharmaceutical industry. His innovative approaches, as witnessed in his latest patents, hold the potential to advance the synthesis and production of important pharmaceutical compounds. Collaborating with experts in the field further solidifies his commitment to progress and innovation within the industry. Burgos' contributions to medicinal chemistry have made a lasting impact, positively influencing the quality and efficacy of pharmaceutical products.